SABS
NASDAQ · Biotechnology
Sab Biotherapeutics Inc
$3.22
-0.08 (-2.28%)
SABS News5 articles
American Airlines Disability Case Raises Policy Execution Questions
A boarding dispute involving a passenger with Down syndrome tests American Airlines' policy execution, not technology. Improved bumping data offers context for investors.
Space Stocks Shed $89 Billion as Chinese Reusable Rocket Test Rattles Sector
A basket of space stocks dropped 5.9% on Monday, erasing $89 billion in market value, as China's reusable rocket test and rising oil prices fueled investor concerns.
China's Reusable Rocket Milestone Fuels $3.3 Billion Rally in Satellite Stocks
Shares of China Spacesat and China Satellite Communications hit daily limits after China's first rocket stage recovery, adding $3.3 billion in combined market value.
Sable Offshore Shares Plunge 48% on Dilution Fears From $100M Stock Sale
Sable Offshore shares tumbled 48.5% as its $100 million stock sale could nearly double dilution due to the lower share price, part of a broader refinancing package.
Blue Origin Achieves Key Reusability Milestone with New Glenn Booster Landing
Blue Origin recovered a previously flown New Glenn rocket booster following the launch of AST SpaceMobile's BlueBird 7 satellite, marking its first successful reuse mission and advancing competition in the reusable launch sector.